» Articles » PMID: 25672029

Renal Tubular Dysfunction Associated with Tenofovir Therapy

Overview
Specialty General Medicine
Date 2015 Feb 13
PMID 25672029
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To describe the i ncidence a nd cha racteristics of Tenofovir (TDF) induced nephrotoxicity among people living with HIV AIDS (PLHA) receiving TDF based anti-retroviral therapy (ART) at Christian Medical College, Vellore.

Method: Medical record review of all the PLHA who is being enrolled and followed up at the ART clinic at CMC, Vellore.

Results: From 2006-11, a total of 274 PLHA have been initiated on TDF based ART. 10 (3.6%) patients developed TDF induced renal dysfunction after a mean duration of 42.6 (SD 19.5) months. 5 patients were female. At the time of initiation of TDF, the mean age was 41.2 (SD 6.1) years and CD4 T-cell count was 281.2 (SD 241.3) cells/μL. 9 patients were started on an NNRTI-based regimen, while only 1 was on a Pl/r-based regimen. 5 patients were asymptomatic. Out of the 5 symptomatic patients, 3 patients complained of anorexia and tiredness only; 1 patient had bone pains and proximal pelvic girdle muscle weakness only while 1 patient had both anorexia and proximal pelvic girdle muscle weakness. Urine examination of 8 patients (all symptomatic and 4 asymptomatic patients) revealed proteinuria on urine dip stick assay (1+ to 3+) without active sediments. 9 patients had decline in the estimated creatinine clearance from mean of 84.1 (SD 21.0) to 62.1 (SD 26.3) mL/min/1.73 m2. The mean plasma phosphate level was 2.08 (SD 0.45) mg/ dL. The mean alkaline phosphatase level increased from 130.7 to 290.8 U/L. Seven patients had features of Fanconi syndrome. All symptomatic patients showed clinical improvement within 2-7 months of discontinuation ofTDF and supplementation of phosphate and calcium.

Conclusion: TDF-associated renal dysfunction has a long incubation period during which the patients are largely asymptomatic and reversible. Hence laboratory confirmation is essential with creatinine clearance, urine examination, and phosphate levels. Prompt change of TDF leads to almost complete resolution of the tubular dysfunction.

Citing Articles

Simultaneous Occurrence of Nephrolithiasis, Fanconi Syndrome, and Nephro-osteopathy in a Patient on First-line Antiretroviral Therapy - A Case Report.

Mangal V, Murari T, Gaikwad S, Kaur K Indian J Nephrol. 2022; 32(2):175-178.

PMID: 35603118 PMC: 9121715. DOI: 10.4103/ijn.IJN_456_20.


Analysis of antiretroviral therapy modification in routine clinical practice in the management of HIV infection.

Sobrino-Jimenez C, Jimenez-Nacher I, Moreno-Ramos F, Gonzalez-Fernandez M, Freire-Gonzalez M, Gonzalez-Garcia J Eur J Hosp Pharm. 2019; 24(2):96-100.

PMID: 31156912 PMC: 6451621. DOI: 10.1136/ejhpharm-2016-000944.


Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.

Jablonowska E, Siwak E, Bociaga-Jasik M, Gasiorowski J, Kalinowska A, Firlag Burkacka E PLoS One. 2019; 14(1):e0210476.

PMID: 30653541 PMC: 6336297. DOI: 10.1371/journal.pone.0210476.


Dual therapy based on raltegravir and boosted protease inhibitors - the experience of Polish centers.

Jablonowska E, Pulik P, Kalinowska A, Gasiorowski J, Parczewski M, Bociaga-Jasik M Arch Med Sci. 2018; 14(4):860-864.

PMID: 30002705 PMC: 6040130. DOI: 10.5114/aoms.2016.62445.


Hypokalemic paralysis secondary to tenofovir induced fanconi syndrome.

Ramteke V, Deshpande R, Srivastava O, Wagh A Indian J Sex Transm Dis AIDS. 2015; 36(2):198-200.

PMID: 26692618 PMC: 4660566. DOI: 10.4103/0253-7184.167176.